MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Principal trial objectives were To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, even though on the li... https://johna443sep7.wikigiogio.com/user